Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy

Kristen L. Zakian, Amita Shukla-Dave, Paul Meyers, Richard Gorlick, John Healey, Howard T. Thaler, Andrew G. Huvos, David M. Panicek, Jason A. Koutcher

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It has been hypothesized that the 31Phosphorus (31P) nuclear magnetic resonance spectrum from certain tumors may provide prognostic information. The goal of the present study was to identify prognostic metabolic markers by using proton-decoupled phosphorus magnetic resonance spectroscopic imaging (31P MRSI). Twenty patients with bone [osteogenic (OS) and Ewing's (ES) and/or primitive neuroectodermal tumor (PNET)] sarcoma, treated with chemotherapy and surgery or with chemotherapy alone, underwent 31P MRSI studies pre- and post-therapy. The studies were performed on a 1.5 Tesla General Electric (GE) clinical scanner equipped with a stand-alone proton decoupler and a dual 1H/31P surface coil pair. The limited sensitivity of the 31p nucleus required that a large soft tissue component of the disease be located within 10 cm (maximum distance) of the body surface and the use of a highly sensitive coil placed near the skin surface. Proton decoupling and nuclear Overhauser enhancement were used to improve the spectral resolution and signal:noise ratio. Baseline 31P spectral features and metabolic changes with treatment were compared with treatment outcome. The patients were categorized depending on survival as event-free survivors or those who died. The pretreatment nucleoside triphosphate:inorganic phosphate (NTP:Pi) ratio, an index of tumor bioenergetic status, was significant (P = 0.003) in differentiating event-free survivors versus those who died. The pretreatment NTP:Pi was higher in patients who were destined to undergo a durable event-free survival compared with those who died. The results are promising, although a prospective study is necessary for confirmation. 31P MRSI appears to be a useful tool for the prediction of survival before therapy in bone sarcomas.

Original languageEnglish (US)
Pages (from-to)9042-9047
Number of pages6
JournalCancer Research
Volume63
Issue number24
StatePublished - Dec 15 2003
Externally publishedYes

Fingerprint

Sarcoma
Phosphorus
Protons
Magnetic Resonance Spectroscopy
Bone and Bones
Nucleosides
Disease-Free Survival
Survivors
Phosphates
Primitive Neuroectodermal Tumors
Drug Therapy
Therapeutics
Energy Metabolism
Neoplasms
Magnetic Resonance Imaging
Prospective Studies
Skin
Survival
triphosphoric acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zakian, K. L., Shukla-Dave, A., Meyers, P., Gorlick, R., Healey, J., Thaler, H. T., ... Koutcher, J. A. (2003). Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy. Cancer Research, 63(24), 9042-9047.

Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy. / Zakian, Kristen L.; Shukla-Dave, Amita; Meyers, Paul; Gorlick, Richard; Healey, John; Thaler, Howard T.; Huvos, Andrew G.; Panicek, David M.; Koutcher, Jason A.

In: Cancer Research, Vol. 63, No. 24, 15.12.2003, p. 9042-9047.

Research output: Contribution to journalArticle

Zakian, KL, Shukla-Dave, A, Meyers, P, Gorlick, R, Healey, J, Thaler, HT, Huvos, AG, Panicek, DM & Koutcher, JA 2003, 'Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy', Cancer Research, vol. 63, no. 24, pp. 9042-9047.
Zakian KL, Shukla-Dave A, Meyers P, Gorlick R, Healey J, Thaler HT et al. Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy. Cancer Research. 2003 Dec 15;63(24):9042-9047.
Zakian, Kristen L. ; Shukla-Dave, Amita ; Meyers, Paul ; Gorlick, Richard ; Healey, John ; Thaler, Howard T. ; Huvos, Andrew G. ; Panicek, David M. ; Koutcher, Jason A. / Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy. In: Cancer Research. 2003 ; Vol. 63, No. 24. pp. 9042-9047.
@article{3e24fc61ae6b490589df2f39ce7d4d8d,
title = "Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy",
abstract = "It has been hypothesized that the 31Phosphorus (31P) nuclear magnetic resonance spectrum from certain tumors may provide prognostic information. The goal of the present study was to identify prognostic metabolic markers by using proton-decoupled phosphorus magnetic resonance spectroscopic imaging (31P MRSI). Twenty patients with bone [osteogenic (OS) and Ewing's (ES) and/or primitive neuroectodermal tumor (PNET)] sarcoma, treated with chemotherapy and surgery or with chemotherapy alone, underwent 31P MRSI studies pre- and post-therapy. The studies were performed on a 1.5 Tesla General Electric (GE) clinical scanner equipped with a stand-alone proton decoupler and a dual 1H/31P surface coil pair. The limited sensitivity of the 31p nucleus required that a large soft tissue component of the disease be located within 10 cm (maximum distance) of the body surface and the use of a highly sensitive coil placed near the skin surface. Proton decoupling and nuclear Overhauser enhancement were used to improve the spectral resolution and signal:noise ratio. Baseline 31P spectral features and metabolic changes with treatment were compared with treatment outcome. The patients were categorized depending on survival as event-free survivors or those who died. The pretreatment nucleoside triphosphate:inorganic phosphate (NTP:Pi) ratio, an index of tumor bioenergetic status, was significant (P = 0.003) in differentiating event-free survivors versus those who died. The pretreatment NTP:Pi was higher in patients who were destined to undergo a durable event-free survival compared with those who died. The results are promising, although a prospective study is necessary for confirmation. 31P MRSI appears to be a useful tool for the prediction of survival before therapy in bone sarcomas.",
author = "Zakian, {Kristen L.} and Amita Shukla-Dave and Paul Meyers and Richard Gorlick and John Healey and Thaler, {Howard T.} and Huvos, {Andrew G.} and Panicek, {David M.} and Koutcher, {Jason A.}",
year = "2003",
month = "12",
day = "15",
language = "English (US)",
volume = "63",
pages = "9042--9047",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy

AU - Zakian, Kristen L.

AU - Shukla-Dave, Amita

AU - Meyers, Paul

AU - Gorlick, Richard

AU - Healey, John

AU - Thaler, Howard T.

AU - Huvos, Andrew G.

AU - Panicek, David M.

AU - Koutcher, Jason A.

PY - 2003/12/15

Y1 - 2003/12/15

N2 - It has been hypothesized that the 31Phosphorus (31P) nuclear magnetic resonance spectrum from certain tumors may provide prognostic information. The goal of the present study was to identify prognostic metabolic markers by using proton-decoupled phosphorus magnetic resonance spectroscopic imaging (31P MRSI). Twenty patients with bone [osteogenic (OS) and Ewing's (ES) and/or primitive neuroectodermal tumor (PNET)] sarcoma, treated with chemotherapy and surgery or with chemotherapy alone, underwent 31P MRSI studies pre- and post-therapy. The studies were performed on a 1.5 Tesla General Electric (GE) clinical scanner equipped with a stand-alone proton decoupler and a dual 1H/31P surface coil pair. The limited sensitivity of the 31p nucleus required that a large soft tissue component of the disease be located within 10 cm (maximum distance) of the body surface and the use of a highly sensitive coil placed near the skin surface. Proton decoupling and nuclear Overhauser enhancement were used to improve the spectral resolution and signal:noise ratio. Baseline 31P spectral features and metabolic changes with treatment were compared with treatment outcome. The patients were categorized depending on survival as event-free survivors or those who died. The pretreatment nucleoside triphosphate:inorganic phosphate (NTP:Pi) ratio, an index of tumor bioenergetic status, was significant (P = 0.003) in differentiating event-free survivors versus those who died. The pretreatment NTP:Pi was higher in patients who were destined to undergo a durable event-free survival compared with those who died. The results are promising, although a prospective study is necessary for confirmation. 31P MRSI appears to be a useful tool for the prediction of survival before therapy in bone sarcomas.

AB - It has been hypothesized that the 31Phosphorus (31P) nuclear magnetic resonance spectrum from certain tumors may provide prognostic information. The goal of the present study was to identify prognostic metabolic markers by using proton-decoupled phosphorus magnetic resonance spectroscopic imaging (31P MRSI). Twenty patients with bone [osteogenic (OS) and Ewing's (ES) and/or primitive neuroectodermal tumor (PNET)] sarcoma, treated with chemotherapy and surgery or with chemotherapy alone, underwent 31P MRSI studies pre- and post-therapy. The studies were performed on a 1.5 Tesla General Electric (GE) clinical scanner equipped with a stand-alone proton decoupler and a dual 1H/31P surface coil pair. The limited sensitivity of the 31p nucleus required that a large soft tissue component of the disease be located within 10 cm (maximum distance) of the body surface and the use of a highly sensitive coil placed near the skin surface. Proton decoupling and nuclear Overhauser enhancement were used to improve the spectral resolution and signal:noise ratio. Baseline 31P spectral features and metabolic changes with treatment were compared with treatment outcome. The patients were categorized depending on survival as event-free survivors or those who died. The pretreatment nucleoside triphosphate:inorganic phosphate (NTP:Pi) ratio, an index of tumor bioenergetic status, was significant (P = 0.003) in differentiating event-free survivors versus those who died. The pretreatment NTP:Pi was higher in patients who were destined to undergo a durable event-free survival compared with those who died. The results are promising, although a prospective study is necessary for confirmation. 31P MRSI appears to be a useful tool for the prediction of survival before therapy in bone sarcomas.

UR - http://www.scopus.com/inward/record.url?scp=0347320777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347320777&partnerID=8YFLogxK

M3 - Article

C2 - 14695223

AN - SCOPUS:0347320777

VL - 63

SP - 9042

EP - 9047

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -